MiLaboratories, a leader in computational biology innovation, is excited to announce the successful completion of its Series A funding round, led by Madrid-based Kfund, with additional support from Speedinvest and other notable international investors. This funding milestone coincides with the launch of its advanced Platforma.bio Software Development Kit (SDK), a groundbreaking tool designed to streamline and enhance how biologists analyze and derive insights from next-generation sequencing data.
Empowering Biologists to Tackle NGS Data Challenges and Accelerate Genomic Research
Biotech and pharmaceutical companies often struggle with integrating next-generation sequencing (NGS) technology, particularly concerning computational infrastructure and scalability. A significant challenge arises from biologists’ dependence on bioinformaticians to analyze the vast amounts of genomic data produced by NGS. This reliance can lead to bottlenecks, as bioinformatic teams are frequently overwhelmed, causing delays in research and actionable insights.
Additional challenges include data interoperability issues, high scaling costs, and the complexity of managing large datasets, which collectively hinder progress in drug discovery and research.
To address these obstacles, MiLaboratories has developed a high-performance software platform that empowers biologists to independently analyze NGS data. By offering an intuitive and scalable solution, MiLaboratories reduces the need for bioinformatic support, speeds up data processing, and seamlessly integrates with existing systems, enhancing collaboration in genomics.
Platforma.bio SDK: Tools for Simplified Computational Analysis
Platforma.bio features a user-friendly, UI-centric design that makes advanced computational biology tools accessible to scientists without the steep learning curve associated with traditional systems. Researchers can focus on their work while the platform automates resource management, data handling, and complex processes.
In line with MiLaboratories’ commitment to academic research, the Platforma.bio Software Development Kit (SDK) is available from their open marketplace and is free for academic scientists, allowing them to develop custom analytical tools and applications. This open, collaborative approach fosters innovation and accelerates discovery by enabling researchers to tailor solutions to their specific needs.
“We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting a new standard in biomedical research,” said Stan Poslavsky, CEO of MiLaboratories. “Today, therapy development relies on data, algorithms, and AI. Our mission is to make cutting-edge computational advances accessible to researchers working towards new drug discoveries.”
Attracting Talent to Drive Market Transformation
With a multi-billion dollar global market potential, MiLaboratories aims to significantly scale its operations by attracting top-tier talent and strategically expanding its presence, particularly in the United States.
“Investing in platforms that bridge the gap between developers (bioinformaticians) and business users (biologists) is central to our fund’s mission. There is tremendous potential in democratizing access to complex data and delivering immunological insights,” remarked Miguel Arias, General Partner of Kfund.
About MiLaboratories
MiLaboratories is a leader in computational biology, creating innovative software solutions that redefine biological research and development. Committed to empowering users, MiLaboratories equips the scientific community with adaptable, cutting-edge tools designed to meet the evolving demands of bioinformatics and biomedical research.
